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Introduction: While retrospective analyses support an association 
between early tumor recurrence and tumor suppressor gene promoter 
methylation in early-stage non–small-cell lung cancers (NSCLCs), 
few studies have investigated this question prospectively.
Methods: Primary tumor tissue from patients with resected patho-
logic stage I to IIIA NSCLCs was collected at the time of surgery 
and analyzed for promoter methylation via methylation-specific 
reverse transcriptase polymerase chain reaction (MethyLight). The 
primary objective was to determine an association between promoter 
methylation of 10 individual tumor suppressor genes (CDKN2A, 
CDH13, RASSF1, APC, MGMT, GSTP1, DAPK1, WIF1, SOCS3, and 
ADAMTS8) and recurrence-free survival (RFS), with the secondary 
objectives of determining association with overall survival (OS), and 
relation to clinical or pathologic features.
Results: A total of 107 patients had sufficient tumor tissue for suc-
cessful promoter methylation analysis. Majority of patients were 
former/current smokers (88%) with lung adenocarcinoma (78%) 
and pathologic stage I disease (62%). Median follow-up was 4 
years. When controlled for pathologic stage, promoter methylation 
of the individual genes CDKN2A, CDH13, RASSF1, APC, MGMT, 
GSTP1, DAPK1, WIF1, and ADAMTS8 was not associated with RFS. 
Promoter methylation of the same genes was not associated with OS 
except for DAPK1 which was associated with improved OS (p = 
0.03). The total number of genes with methylated promoters did not 
correlate with RFS (p = 0.89) or OS (p = 0.55).
Conclusion: Contrary to data established by previous retrospec-
tive series, tumor suppressor gene promoter methylation (CDKN2A, 
CDH13, RASSF1, APC, MGMT, GSTP1, DAPK1, WIF1, and 
ADAMTS8) was not prognostic for early tumor recurrence in this 
prospective study of resected NSCLCs.
Key Words: Non–small-cell lung cancer, Resected, Promoter meth-
ylation, Epigenetics, Tumor suppressor gene
(J Thorac Oncol. 2014;9: 1272–1277)
Lung cancer development is characterized by the acquisition of multiple methylation changes that drive the carcinogenic 
sequence.1,2 Many of these changes target tumor suppres-
sor genes (TSGs) that control specific processes such as cell 
cycle regulation (CDKN2A), the development of an invasive 
phenotype (CDH13), and RAS and WNT signaling (RASSF1 
and APC, respectively).3 While multiple retrospective series 
have demonstrated a negative prognostic association between 
tumor suppressor gene promoter methylation and outcomes in 
early-stage lung cancers,4,5 few studies have asked this ques-
tion prospectively.
In 2008, a nested case–control study of stage I non–
small-cell lung cancers was published by Brock et al.6 in 
the New England Journal of Medicine. The primary objec-
tive of this retrospective study was to determine the associa-
tion between tumor suppressor gene methylation and disease 
recurrence. Patients who had early recurrence of their cancer 
(≤40 months) after curative surgery were matched against a 
cohort of patients who did not have recurrent disease within 
40 months. Tumor tissue was tested for promoter methylation 
of CDKN2A (P16), CDH13, RASSF1, and APC. The study 
showed that an increasing number of genes with methylated 
promoters (0, 1–2, 3–4 genes methylated) in primary tumor 
tissue was significantly associated with poorer recurrence-
free survival (RFS) (p = 0.001). On multivariate analysis of 
the original cohort along with a separate validation cohort, 
when CDKN2A or CDH13 were methylated in the primary 
tumor, the odds ratios for recurrence were 3.55 (1.77–7.13, 
p < 0.001) and 2.33 (1.16–4.69, p = 0.02), respectively.
Concurrent with this publication, we were conducting 
a prospective biomarker protocol with a similar objective 
of establishing an association between RFS and promoter 
methylation. The same four genes and six other tumor sup-
pressor genes (MGMT, GSTP1, DAPK1, WIF1, SOCS3, and 
ADAMTS8) were tested for promoter methylation in both 
resected tumor and serial plasma samples. We herein report 
the results of this study in an attempt to validate the findings 
published by Brock and colleagues6 in a prospective fashion in 
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stage I to IIIA non–small-cell lung cancers (NSCLCs) while 
providing additional data on the utility of promoter methyla-
tion of other tumor suppressor genes as potential biomarkers.
PATIENTS AND METHODS
Patients with clinical stage I to IIIA NSCLCs who 
were treated at Memorial Sloan Kettering Cancer Center and 
deemed to have resectable disease were eligible for enrollment 
onto this prospective, institutional review board-approved 
protocol. Subjects who received neoadjuvant therapy of any 
kind (chemotherapy, radiotherapy, or investigational agents) 
were excluded. All patients underwent surgical resection of 
their cancer with curative intent. Tumors from those with 
pathologic stage I to IIIA disease and in whom an R0 resec-
tion was achieved were sent for promoter methylation analy-
sis. Pathologic staging followed the 2009 TNM International 
System for Staging Lung Cancer.7 Stage-appropriate adjuvant 
therapy including chemotherapy and/or radiation therapy were 
administered as per the treating physician.
Sample Acquisition and Promoter 
Methylation Analysis
Both primary tumor tissue and serial plasma samples 
were acquired for promoter methylation analysis. Fresh frozen 
tumor tissue was obtained at the time of surgical resection. 
Plasma samples were collected at four different time points 
during the study course: immediately before surgical interven-
tion, 3 to 8 days postsurgery, 2 to 5 weeks postsurgery, and at 
2 to 4 months postsurgery.
Tumor and plasma samples were analyzed via methyl-
ation-specific reverse transcriptase polymerase chain reaction 
(MethyLight, Response Genetics, Los Angeles, CA). Assay 
sensitivity allowed the potential detection of a single methyl-
ated allele in the presence of a 10,000-fold excess of unmeth-
ylated alleles.8 The promoter regions of the following panel of 
10 genes were analyzed: CDKN2A, CDH13, RASSF1, APC, 
MGMT, GSTP1, DAPK1, WIF1, SOCS3, and ADAMTS8. 
These genes were chosen as targets of interest based on their 
roles as regulators of cancer growth and their inclusion in pre-
vious retrospective series.3,4,9 DNA was isolated from fixed 
volumes of tumor and plasma and subjected to bisulfite treat-
ment using a Qiagen Epitect Bisulfite kit. Fully methylated 
Qiagen EpiTect Control DNA was used as a positive control. 
Human genomic DNA from peripheral blood mononuclear 
cells (Ambion) was used as a negative control.
After bisulfite treatment, genomic DNA was ampli-
fied by fluorescence-based, real-time quantitative PCR using 
locus-specific PCR primers flanking an oligonucleotide probe 
with a 5′ fluorescent reporter dye (6FAM) and a 3′ quencher 
dye (TAMRA). 5′ to 3′ nuclease activity of Taq DNA poly-
merase resulted in cleavage of the 5′ probe, releasing the fluo-
rescent reporter. Reporter fluorescence was detected by the 
laser ABI Prism 7900 Sequence Detection System (Perkin-
Elmer, Foster City, CA). Primer and probe design for each 
of the 10 genes was based on previous reports and is detailed 
in Supplementary Table 1 (Supplemental Digital Content, 
http://links.lww.com/JTO/A654).10–13 Promoter methylation 
was reported as a methylation value percentage (MVP) with 
tumor suppressor gene levels normalized to β-Actin in modi-
fied DNA.
Statistical Analysis
The primary objective of this study was to determine the 
association between promoter methylation of individual tumor 
suppressor genes (in tumor and plasma) and RFS. Secondary 
objectives included determination of the association between 
promoter methylation and overall survival (OS) or clinicopath-
ologic features. RFS and OS were calculated from the time 
of surgical resection using Kaplan–Meier estimates. Patients 
were followed for RFS until recurrence or death, whichever 
came first, and for OS until death of any cause. Patients who 
did not experience the event of interest during the study time 
were censored at the time of the last available follow-up.
For each individual tumor suppressor gene, patients 
whose tumors had methylated promoters were compared with 
those with unmethylated promoters with respect to RFS and 
OS using the log-rank test after adjusting for pathologic stage.14 
In addition, the log-rank test was used to assess whether the 
total number of methylated tumor suppressor gene promoters 
per patient was associated with RFS and OS. Comparisons 
were performed within each stage and the results aggregated 
over all stages. To facilitate comparison with data presented 
by Brock et al.,6 we also undertook an analysis restricted to 
patients diagnosed with stage I disease.
For the purposes of this study, any non-zero MVP value 
for each individual tumor suppressor gene was deemed posi-
tive for promoter methylation. The incidence of promoter 
methylation of individual tumor suppressor genes was corre-
lated with tumor morphology, histology, and pathologic stage. 
Group comparisons were performed with the log-rank test and 
Cox-proportional hazards.
RESULTS
A total of 346 patients with clinical stage I to IIIA 
NSCLCs who were deemed to have resectable disease at the 
time of diagnosis were identified between 2003 and 2008 at 
the Memorial Sloan Kettering Cancer Center. Subjects for 
whom neoadjuvant therapy was planned were excluded and 
220 patients were enrolled onto this trial. Of these patients, 
28 were excluded (23 found to have stage IIIB–IV during 
workup, and five patients with an R1 resection). One hundred 
and ninety-seven successfully underwent resection of all gross 
and microscopic disease (R0) and were found to have patho-
logic stage I to IIIA disease. As majority of patients had early-
stage disease, only 156 had available tissue for further testing 
after pathologic review. After specimen processing, sufficient 
tumor tissue for successful promoter gene methylation analy-
sis was available in 107 cases. Of these cases, plasma samples 
were drawn for all four time points (preoperatively and 3–8 
days, 2–5 weeks, and 2–4 months postsurgery) in 74 patients.
Patient Characteristics and Promoter 
Methylation Frequency in Tumors
The characteristics of patients whose tumors were suc-
cessfully analyzed for promoter gene methylation (n = 107) 
are presented in Table 1. The majority of patients were current 
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or former smokers (88%, n = 84) with lung adenocarcinoma 
(78%, n = 83) and pathologic stage I disease (62%, n = 66). 
Patients with pathologic stage II and IIIA disease comprised 
25% (n = 27) and 13% (n = 14) of the population, respectively. 
The median duration of follow-up on this study was 4 years. 
In relation to the primary end point of RFS, the large majority 
of recurrences would have been expected to occur within this 
period.
Promoter methylation in primary tumor tissue was a 
frequently observed event for the following tumor suppressor 
genes: CDH13, WIF1, DAPK1, APC, and RASSF1 (occurring 
in 87%, 64%, 62%, 57%, and 50% of tumors, respectively). 
Four of the remaining genes on the panel including ADAMTS8, 
CDKN2A, MGMT, and GSTP1 were less often methylated 
(36%, 31%, 8%, and 5%, respectively). SOCS3 was not found 
to be methylated in any samples (Fig. 1). Consequently, the 
association between SOCS3 and either recurrence-free or OS 
could not be analyzed. A significant variability in absolute 
MVP values was noted between individual tumor suppressor 
genes.
Association Between Tumor Promoter 
Gene Methylation and Survival
When controlled for pathologic stage, promoter methyl-
ation of the individual genes APC, CDH13, MGMT, RASSF1, 
WIF1, ADAMTS8, GSTP1, and CDKN2A in primary tumor 
tissue was not significantly associated with RFS. Similarly, 
promoter methylation of the same genes in primary tumor 
tissue was not associated with OS. For each of these genes, 
median RFS and OS for patients with either methylated or 
unmethylated promoters are detailed in Table 2. These lack of 
an association between promoter methylation of these genes, 
and RFS and OS was confirmed in a subset analysis of patients 
with stage I disease.
Across the entire panel of 10 genes, the total number 
of methylated tumor suppressors per tumor (0–2, 3, 4, 5, or 
6–8 methylated genes per sample) did not correlate with either 
RFS (p = 0.89) or OS (p = 0.55).
A nonsignificant trend toward improved RFS was 
noted in patients whose tumors harbored a methylated ver-
sus unmethylated DAPK1 promoter (4.9 versus 2.8 months, 
p = 0.09). DAPK1 promoter methylation, however, was sig-
nificantly associated with improved OS. Patients who had 
tumors with an unmethylated DAPK promoter had a median 
OS of 4.2 months, whereas median OS was not reached for 
those whose tumors harbored a methylated DAPK1 promoter 
(p = 0.03). This was confirmed in a subset analysis of patients 
with stage I disease (median OS of patients with unmethyl-
ated versus methylated DAPK promoters: 5.2 months versus 
not reached, p = 0.03).
Tumor Promoter Gene Methylation 
and Pathologic Features
RASSF1 promoter methylation was more likely to be 
present in tumors of poorly differentiated or undifferentiated 
morphology versus tumors of moderately differentiated or 
well-differentiated morphology (64% versus 4%, p = 0.03).
Promoter methylation of CDKN2A was more prevalent 
in SQCLCs (55%) in comparison to ADCLs (26%) and large 
cell carcinomas (17%, p = 0.03). ADCLs had a higher fre-
quency of APC promoter methylation (65%) compared with 
large cell carcinomas (50%) and SQCLCs (30%, p = 0.02).
Promoter methylation of WIF1 was significantly associ-
ated with increasing pathologic T stage (38%, 61%, 71%, and 
87% for pT1a, pT1b, pT2a, and pT2b, respectively, p = 0.01). 
In addition, promoter methylation of GSTP1 was significantly 
associated with increasing pathologic N stage (3%, 5%, and 
21% for pN0, pN1, and pN2, respectively, p = 0.03). These are 
depicted in Figure 2.
Promoter methylation of the remaining individual genes 
APC, MGMT, GSTP1, DAPK, CDH1, and ADAMTS8 was not 
associated with tumor morphology, histology, or pathologic 
stage.
Promoter Gene Methylation in Blood
For plasma tumor suppressor gene methylation analysis, 
the number of patients with non-zero MVP values at each pre-
specified time point was exceedingly low. Because of the lack 
of variability in blood promoter gene methylation values, we 
could not formally evaluate the association between methyla-
tion status and survival outcomes or clinical features.
DISCUSSION
Epigenetic changes have long been touted as ideal bio-
marker candidates due to their early acquisition15 and roles 
in tumorigenesis.16 Our findings confirm that tumor sup-
pressor gene promoter methylation is a common event in 
TABLE 1.  Demographics
Patient Characteristics n %
Age
  Median 68 years (43–85)
Sex
  Male 55 51
  Female 52 49
Smoking
  Current 20 19
  Former 74 69
  Never 13 12
Stage
  IA 37 35
  IB 29 27
  IIA 17 16
  IIB 10 9
  IIIA 14 13
Pathology
  Adenocarcinoma 83 78
  Squamous cell carcinoma 20 19
  Large cell carcinoma 4 12
The clinical characteristics of 107 patients with resected non–small-cell lung 
cancers whose tumors successfully underwent promoter methylation gene analysis are 
summarized.
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NSCLCs,5,17,18 the prevalence of which exceeds half of all 
tumors tested for CDH13, WIF1, DAPK1, and APC. While 
these events are common, data regarding their roles as strong 
predictors of outcome in early-stage lung cancers has relied 
largely on retrospective series, limiting the utility of these 
observations.
In this prospective series of resected, early-stage lung 
cancers, we did not detect an association between RFS and 
tumor promoter methylation of CDKN2A, CDH13, RASSF1, 
and APC in addition to five other genes on our panel (MGMT, 
GSTP1, DAPK, WIF1, and ADAMTS8). These results were 
confirmed in a subset analysis of patients with stage I disease, 
comparable but not completely similar to the patient popu-
lation analyzed in the Brock series.6 In addition, we did not 
confirm that an increasing number of genes with methylated 
promoters was associated with poorer RFS. Promoter meth-
ylation was not associated with OS, except for DAPK where 
methylation was found to be associated with improved sur-
vival. The significance of this finding remains unclear as 
previous studies have reported a negative impact of DAPK 
methylation on survival outcomes.5,19 Similarly, the number 
of methylated tumor suppressor gene promoters did not cor-
relate with OS. Future confirmatory studies would benefit 
from the inclusion of a validation set to add strength to these 
conclusions.
Despite their lack of prognostic significance, the profile 
of tumor suppressor gene promoter methylation in early-stage 
lung cancers continues to contribute important information 
regarding tumor biology. We herein confirm a high frequency 
of promoter methylation of CDKN2A in squamous cell lung 
FIGURE 1.  Frequency of promoter gene meth-
ylation in resected stage I to IIIA NSCLCs. The 
percentage of tumors with methylated promoter 
regions of 10 tumor suppressor genes is depicted. 
Genes whose promoter regions were found to 
be methylated in at least 50% of samples tested 
include CDH13 (87%), WIF1 (64%), DAPK (62%), 
APC (57%), and RASSF1A (50%). ADAMTS8 
(36%), CDKN2A (31%), MGMT (8%), and GSTP1 
(5%) were less often methylated. SOCS3 was not 
found to be methylated in any samples.
TABLE 2.  Association Between Tumor Suppressor Gene Promoter Methylation and Survival
Gene Methylation Results Median RFS p Value Median OS p Value
CDH13 Methylated (87%, n = 93)
Unmethylated (13%, n = 14)
4.5 mo
2.7 mo
0.43
6.2 mo
4.4 mo
0.59
WIF1 Methylated (64%, n = 69)
Unmethylated (36%, n = 38)
4.5 mo
3.9 mo
0.49
6.2 mo
NR
0.57
DAPK1 Methylated (62%, n = 66)
Unmethylated (38%, n = = 41)
4.9 mo
2.8 mo
0.09
NR
4.2 mo
0.03
APC Methylated (57%, n = 62)
Unmethylated (43%, n = 45)
3.5 mo
5.0 mo
0.56
4.3 mo
NR
0.07
RASSF1 Methylated (50%, n = 54)
Unmethylated (50%, n = 53)
4.0 mo
4.5 mo
0.86
5.3 mo
NR
0.67
ADAMTS8 Methylated (36%, n = 38)
Unmethylated (64%, n = 69)
5.0 mo
3.8 mo
0.49
6.2 mo
5.3 mo
0.71
CDKN2A Methylated (31%, n = 33)
Unmethylated (68%, n = 74)
4.9 mo
3.9 mo
0.60
6.1 mo
6.2 mo
0.72
MGMT Methylated (8%, n = 9)
Unmethylated (92%, n = 98)
3.4 mo
4.3 mo
0.92
4.2 mo
6.2 mo
0.65
GSTP1 Methylated (5%, n = 6)
Unmethylated (95%, n = 101)
3.6 mo
4.5 mo
0.95
4.2 mo
6.2 mo
0.81
SOCS3 Methylated (0%, n = 0)
Unmethylated (100%, n = 107)
–
–
–
–
–
–
Median recurrence-free survival (RFS) and overall survival (OS) for patients with both methylated and unmethylated promoters of 10 tumor suppressor genes are shown. SOCS3 
was not found to be methylated in any samples and could not be analyzed in relation to RFS or OS.
NR, not reached.
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carcinomas in comparison to other histologies. These results 
echo the findings of genomic characterization of squamous 
lung cancers by The Cancer Genome Atlas where inactiva-
tion of the CDKN2A locus via a variety of mechanisms (epi-
genetic silencing, inactivating mutation, exon skipping, and 
homozygous deletion) was found in 72% of cases analyzed.20 
CDKN2A encodes the protein p16INK4A, a CDK inhibitor that 
blocks the actions of CDK4 and CDK6 that are important for 
cell cycle G1 phase progression. Silencing of CDKN2A results 
in increased CDK4/6 activity and dysregulation of cell cycling 
that may contribute significantly to the pathogenesis of these 
tumors. A large prospective clinical trial for squamous lung 
cancers is planned to contain an arm with a CDK4/6 inhibitor 
for tumors with genomic aberrations thought to contribute to 
cell cycle dysregulation.21
We similarly demonstrate that promoter methylation 
of the tumor suppressor genes RASSF1, WIF1, and GSTP1 
is associated with a poorly differentiated tumors and more 
advanced disease in early-stage lung cancers, respectively. 
RASSF1 encodes the RAS association domain family protein 
1A that mediates the apoptotic effects of the RAS protein.22 
Consistent with the results we present here, several studies 
have established a correlation between gene hypermethylation 
and poorly differentiated histology.23–25 WIF1 (Wnt-inhibitory 
factor-1) hypermethylation has previously been described in 
lung cancers and results in increased activation of the Wnt 
pathway that plays a critical role in stem cell regulation and 
carcinogenesis.26,27 The latter may play a role in the increase 
in nodal disease seen in patients with methylated WIF1 pro-
moters in our series. In contrast, we found GSTP1 promoter 
methylation to be associated with increasing pathologic T 
stage. GSTP1 encodes glutathione S-transferase P, an enzyme 
involved in the metabolism of xenobiotic agents.28,29 The 
mechanism by which silencing of this gene and a putative 
decrease in the activity of the enzyme relate to increasing 
tumor size remains to be determined.
Lastly, while all non-zero MVP values were taken to rep-
resent evidence of promoter gene methylation in this report, 
the range of absolute MVP values varied significantly between 
genes. This heterogeneity and the need for both laboratory 
and clinical validation of existing assays are important issues 
that need to be recognized as we move forward. Whereas the 
presence of a mutation or fusion involving a driver oncogene 
is, for practical purposes, an “all-or-none” phenomenon, the 
degree of promoter methylation varies significantly between 
tumors with a lack of test-specific cutoff values for “positive” 
methylation in quantitative assays. While the assay that we 
used in this trial had the ability to provide semiquantitative data 
regarding the degree of promoter methylation, with 10 genes 
and two outcomes investigated, an exploratory analysis of the 
relationship between the degree of methylation and RFS or OS 
would have had a high risk of generating false-positive results. 
Investigations into epigenetic markers of tumor biology and 
patient outcome will benefit from an increased focus on stan-
dardization of available assays of gene methylation.
In summary, contrary to data published in previous ret-
rospective reports, we failed to demonstrate an association 
between promoter methylation of APC, CDKN2A, MGMT, 
GSTP1, DAPK, CDH1, RASSF1, WIF1, and ADAMTS8 and 
RFS in this prospective study of resected early-stage NSCLCs.
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